^#.^t34: TLC of Antiemetic Drugs

2013 ◽  
pp. 666-669
Keyword(s):  
Antiemetic Drugs

The Effects On Pilot Performance of Antiemetic Drugs Administered Singly And In Combination

1987 ◽  
Author(s):  
Henry L. Taylor ◽  
Fred C. Hyman ◽  
Martha H. Weller ◽  
Robert J. Nagel ◽  
Bruce C. Richardson ◽  
...  
Keyword(s):  
Pilot Performance ◽  
Antiemetic Drugs

The effect of foot reflexology on chemotherapy-induced nausea and vomiting in digestive or lung cancer patients: a randomized controlled trial (Preprint)

2020 ◽  
Author(s):  
Audrey Murat-Ringot ◽  
Pierre Jean Souquet ◽  
Fabien Subtil ◽  
Florent Boutitie ◽  
Marie Preau ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Controlled Trial ◽  
Nausea And Vomiting ◽  
Control Group ◽  
Digestive Cancer ◽  
Complementary Medicines ◽  
Antiemetic Drugs ◽  
Platinum Based Chemotherapy ◽  
Significant Difference ◽  
Delayed Nausea

BACKGROUND Cancer is a chronic disease with an incident worldwide had been 24.5 million and 9.6 million deaths in 2017. Lung and colorectal cancer are the most common cancer for both sexes and according to national and international recommendations platinum-based chemotherapy is the reference adjuvant treatment. This chemotherapy can be moderately to highly emetogenic. Despite antiemetic therapy, chemotherapy-induced nausea and vomiting may persist. Moreover, cancer patient are increasingly interested in alternative and complementary medicines and express the desire that non-pharmacological treatments be used in hospitals. Among alternative and complementary medicines, foot reflexology decreases significantly the severity of chemotherapy-induced nausea and vomiting in breast cancer patients. OBJECTIVE The primary objective of the present study was to assess the benefits of foot reflexology as a complement to conventional treatments on severity of acute chemotherapy-induced nausea and vomiting in digestive or lung cancer patients. The secondary objectives assessed were the frequency and severity of delayed chemotherapy-induced nausea and vomiting, quality of life, anxiety, and self-esteem. METHODS The present study was conducted between April 2018 and April 2020 in French University Hospital. This is an open-label randomized controlled trial. Participants are randomized into two groups: 40 to interventional group (conventional care with foot reflexology) and 40 to control group (conventional care without foot reflexology). Foot reflexology sessions (30 minutes) are performed on an outpatient or inpatient. Eligible participants are patients with a lung or digestive cancer with indication for platinum-based chemotherapy. RESULTS The severity of acute nausea and vomiting was assessed with a visual analogue scale during the second cycle of chemotherapy. A significant increase of at least 2 points was observed for control group (20.6%, P = 0.01). Across all cycle, the foot reflexology group showed a trend towards less frequent delayed nausea (P=0.28), a significantly less frequent consumption of antiemetic drugs (P=0.04), and no significant difference for vomiting (P=0.99); there was a trend towards a perception of stronger severity for delayed nausea in the control group (P=0.39). According to quality of life and anxiety, there was no significant difference between the interventional group and the control group (P=0.32 and P=0.53 respectively). CONCLUSIONS In conclusion, the present study results indicated that foot reflexology decreased significantly the severity of acute nausea and consumption of antiemetic drugs in lung and digestive cancer patients. No side effects from foot reflexology have been noted. In order to better respond to a desire of patients for non-pharmacological treatments and CAMs to be used in hospitals to improve their care, the results of this study showed that foot reflexology seems to be a promising complement to conventional antiemetic drugs. To assess the performance of this intervention in routine practice, a larger study with several health care centers would be relevant with a cluster RCT. CLINICALTRIAL The present study registered with clinicaltrials.gov: NCT03508180 (28/06/2018) INTERNATIONAL REGISTERED REPORT RR2-10.2196/17232

Extrapyramidal reactions to prochlorperazine and similar antiemetic drugs

1963 ◽  
Vol 16 (10) ◽  
pp. 1261-1265 ◽  
Author(s):  
Norman M. Pokras ◽  
B.C. Kingsbury
Keyword(s):  
Antiemetic Drugs

Antiemetic Drugs

2013 ◽  
pp. 23-35
Author(s):  
Matti Aapro ◽  
Karin Jordan ◽  
Petra Feye
Keyword(s):  
Antiemetic Drugs

Antimotion Sickness and Antiemetic Drugs

Drugs ◽  
1979 ◽  
Vol 17 (6) ◽  
pp. 471-479 ◽  
Author(s):  
Charles D. Wood
Keyword(s):  
Antiemetic Drugs

Obtaining and research of pharmaceutical properties of antiemetics in a form of powder for inhalation

2021 ◽  
Author(s):  
Igor M. Ivanov ◽  
Tatiana B. Pechurina ◽  
Nikolai G. Vengerovich ◽  
Mikhail A. Yudin ◽  
Aleksandr S. Nikiforov ◽  
...  
Keyword(s):  
Particle Size ◽  
Dosage Form ◽  
Production Method ◽  
Particle Fraction ◽  
Median Particle Size ◽  
Antiemetic Drugs ◽  
Median Particle ◽  
Pharmaceutical Properties ◽  
Mass Median ◽  
Respirable Particle

Samples of antiemetic drugs (ondansetronum, palonosetronum, metoclopramidum) in the form of powder for inhalation have been developed by the method of spray drying. The granulometric composition, hygroscopicity and aerodynamic distribution of aerosol particles of the drugs have been investigated. The dosage form of the powder for inhalation of antiemetics (ondansetronum and palonosetronum) in terms of its particle size distribution, hygroscopicity and content of the agent corresponds to those for inhalation using dry powder inhalers. In the study of the phase-dispersed composition of aerosol, ondansetronum and palonosetronum in the dosage form of powder for inhalation as part of the HandiHaler inhaler (at a flow rate of 60 l / min) showed high rates of the released dose up to 72-76%, respirable particle fraction (up to 5 m) up to 54 -56% and a mass median particle size of about 3 microns. Obtaining the inhaled form of metoclopramide requires optimization of the production method for receiving the product with acceptable pharmaceutical properties.

scholarly journals Effectiveness of Intraoperative Laser Acupuncture Combined with Antiemetic Drugs for Prevention of Postoperative Nausea and Vomiting

2020 ◽  
Vol 26 (1) ◽  
pp. 67-71
Author(s):  
Neslihan Unsal ◽  
Zeynep Nur Akcaboy ◽  
Ozlem Balkız Soyal ◽  
Erkan Yavuz Akcaboy ◽  
Nevzat Mehmet Mutlu ◽  
...  
Keyword(s):  
Postoperative Nausea ◽  
Postoperative Nausea And Vomiting ◽  
Nausea And Vomiting ◽  
Laser Acupuncture ◽  
Antiemetic Drugs

Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center.

1998 ◽  
Vol 16 (2) ◽  
pp. 771-778 ◽  
Author(s):  
M J Nolte ◽  
R Berkery ◽  
B Pizzo ◽  
L Baltzer ◽  
D Grossano ◽  
...  
Keyword(s):  
Cost Effective ◽  
Chemotherapeutic Agents ◽  
Cancer Site ◽  
Cancer Center ◽  
Antiemetic Drug ◽  
Serotonin Antagonist ◽  
Antiemetic Drugs ◽  
Antiemetic Guidelines ◽  
Disease Site ◽  
High Level

PURPOSE The need to foster the appropriate and cost-effective use of serotonin-antagonist antiemetic drugs spurred the creation of guidelines. The process by which institution-wide guidelines at Sloan-Kettering were developed, implemented, assessed, and modified is described. METHODS A multidisciplinary group working with disease-specific management teams assigned the emetic potential of chemotherapy programs to one of five categories. Antiemetic regimens, including a specified dose and schedule of a serotonin-antagonist and dexamethasone, were assigned to each emetic category. The information was collated by disease site and chemotherapy program into hospital-wide antiemetic regimen recommendations. Quality assessment was conducted initially and repeated each time the guidelines were modified. RESULTS Patient surveys demonstrated a high level of satisfaction with emetic control, which was similar to reported results. Data from the latest survey showed zero emetic episodes in 93% and 87% of participants given moderate and highly emetogenic chemotherapy, respectively. Compliance with the guidelines, initially in 73%, has been improved using a standardized chemotherapy order "check box" labeled, "Antiemetics as per Guidelines." Antiemetic drug expenditures decreased from a projected $2.8 million to $1.3 million annually. CONCLUSION The guidelines became an educational tool that ensured the delivery of optimal antiemetic therapy chosen by professionals with the greatest knowledge of both the particular chemotherapy regimen and cancer site. Implementation of the guidelines resulted in substantial savings while treating more patients. The guidelines were easily modified as new chemotherapeutic agents and antiemetic drugs became available.

Evaluation of the Antiemetic Activity of Bromopride in Cancer Patients Treated with I.V. CMF

1985 ◽  
Vol 71 (5) ◽  
pp. 455-458 ◽  
Author(s):  
Fausto Roila ◽  
Vincenzo Minotti ◽  
Enzo Ballatori ◽  
Carlo Basurto ◽  
Maurizio Tonato
Keyword(s):  
Breast Cancer ◽  
Statistical Analysis ◽  
Protective Effect ◽  
Cancer Patients ◽  
Side Effect ◽  
Double Blind ◽  
Antiemetic Treatment ◽  
Antiemetic Drugs ◽  
Antiemetic Activity ◽  
Positive Lymph Nodes

In more than 70 % of patients undergoing surgery for breast cancer with histologically positive lymph nodes, precautional therapy with CMF (cyclophosphamide, methotrexate, 5-fluorouracil) causes nausea and vomiting. At the present time, the optimal antiemetic therapy has not been found. From May 1983 to March 1984, 35 patients, of whom 34 were evaluable, were entered in a randomized double blind antiemetic treatment with either bromopride (16 patients), a procainamide derivative structurally similar to metoclopramide, or placebo (18 patients). Bromopride (20 mg) and the placebo were administered in a 3-min i.v. injection half an hour before chemotherapy and at 3 ½ and 7 ½ following chemotherapy. A complete antiemetic protection was obtained in 9 patients (56.3 %) treated with bromopride compared to 5 patients (27.8 %) treated with the placebo. A major antiemetic (≤ 2 vomiting episodes) was obtained in 3 patients (18.7 %) treated with bromopride compared to 5 patients (27.8 %) treated with the placebo. Statistical analysis showed a trend in favor of bromopride (P = 0.058). The most frequent side effect was sedation reported in 6 patients (37.5 %) treated with bromopride and 2 patients (11.1 %) treated with the placebo (P = 0.06). The study was interrupted when several patients presented vomiting episodes more than 12 h after CMF administration, and thus beyond the foreseeable protective effect of the antiemetic treatment. It is our opinion that the search for an optimal antiemetic regimen in the course of i.v. CMF therapy should consider the administration of antiemetic drugs at least until 12 h after chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document